Business Context and Reporting Period
This Form 8-K filing by Colgate-Palmolive Company covers events occurring on March 12, 2026. The report details significant changes to the composition of the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
- Board Election: The Board elected Christopher S. Boerner, Ph.D., to the Board of Directors, effective March 15, 2026. Dr. Boerner is currently the Board Chair and CEO of Bristol-Myers Squibb Company.
- Board Departure: Steven A. Cahillane advised the Board that he will not stand for reelection at the Annual Meeting of Stockholders scheduled for May 8, 2026. His departure is attributed to his new role as CEO of The Kraft Heinz Company.
Guidance, Outlook, and Management Commentary
Management commentary highlights that Dr. Boerner brings extensive global business leadership experience and expertise in the pharmaceutical and healthcare industries, which are described as complementary to Colgate-Palmolive's business. No financial guidance, outlook, risks, or contingencies are disclosed in this filing.
Key Facts for Investor Verification
- Verify the effective date of Christopher S. Boerner's board membership (March 15, 2026).
- Confirm the date of the upcoming Annual Meeting of Stockholders (May 8, 2026) where Steven A. Cahillane will not seek reelection.
- Review the Company's proxy statement filed on March 26, 2025, for details on the director compensation program applicable to Dr. Boerner.